GCP
LXEO icon

GSA Capital Partners’s Lexeo Therapeutics LXEO Stock Holding History

GSA Capital Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197K Buy
34,269
+22,806
+199% +$162K 0.01% 1464
2025
Q4 		$114K Buy
+11,463
New +$105K 0.01% 1515
2025
Q3 		– Sell
-14,528
Closed -$58K – 1911
2025
Q2 		$58K Buy
+14,528
New +$47.8K ﹤0.01% 1654

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's LXEO Position: Q1 2026 in Review

GSA Capital Partners increased its Lexeo Therapeutics (LXEO) stake by 199% in Q1 2026, buying an estimated $162K and bringing the position to 34,269 shares worth $197K. The position accounts for 0.01% of the portfolio, ranked #1464.

GSA Capital Partners first reported a position in LXEO in Q2 2025 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • GSA Capital Partners held 34,269 shares of Lexeo Therapeutics worth $197K as of Q1 2026.
  • GSA Capital Partners bought 22,806 Lexeo Therapeutics shares in Q1 2026, an estimated $162K.
  • Lexeo Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1464 holding.
  • GSA Capital Partners first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.